依达拉奉联合丁苯酞胶囊治疗急性缺血性脑卒中的临床研究及安全性分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the research and safety analysis of Edaravone in accordance with the joint in Butyl phthalide capsule in the treatment on acute ischemic stroke.M ethods 83 Patients with acute ischemic stroke from July 2012 to August 2015 in our hospital were selected and randomly dividied into the control group and treatment group. All the patientswere treated with routine treatmentaccording to the guide,while the control group(n=41)were accepted Edaravone in additon,and the treatment group(n=42)were cured with Butyl phthalide capsule on the basis of control group,14 days for a course of treatment.Before and after treatment in patientswith serum hypersensitive c-reactive protein(hs-CRP),tumor necrosis factor(TNF-α)the improvement of inflammatorymarkers were compared.The two groups would be also compared with nerve function(NIHSS score)to improve the situation,clinical curative effect and adverse drug reactions.Results After treatment,the level of the patient hs-CRP,TNF-α,NIHSS scores were lower than before treament,but the treatment group improved more significantly,and the total effective rate was higher,with significant difference(P＜0.05),the incidence of adverse reactions of two groups were low,with no siginificant differences(P＞0.05). Conclusion Curative effect of edaravone in accordance with the joint in phthalide capsule in the treatment on acute ischemic stroke is distinct,which can accelerate disease rehabilitation,inhibit inflammation,it isworth promoting.

Key words： Edaravone Butyl phthalide capsule Acute ischemic stroke Security Inflammation factors NIHSSscore

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Hai-shan
	XIAO Cheng-nian
	XIZhen-hua
	HUANG Peng

Cite this article:

LIANG Hai-shan,XIAO Cheng-nian,XIZhen-hua, et al. The research and safety analysis of Edaravone in accordance w ith the joint in Butyl phthalide capsule in the treatment on acute ischem ic stroke[J]. 中国当代医药, 2016, 23(32): 133-135.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I32/133

[1]	许建强，李永鸿，霍保善，等.乌司他丁联合尿激酶治疗急性脑梗死的效果[J].广东医学，2014，35（14）：2274-2276.
[2]	陈计侠，苏西云，王雪辉，等.长春西汀与胞二磷胆碱治疗脑梗塞对于脑功能恢复疗效的对比[J].临床医药文献杂志，2015，2（1）：21-22.
[3]	王薇薇，王新德.第六届全国脑血管病学术会议纪要[J].中华神经科杂志，2004，37（8）：346－348．
[4]	全国第四届脑血管学术会议.脑卒中患者临床神经功能缺损程度评分标准[J].中华神经科杂志，1996，29（6）：381-383.
[5]	谢骏，莫穗林，李董男.中西医结合治疗腔隙性脑梗死研究进展[J].现代中西医结合杂志，2014，23（11）：1249-1251.
[6]	张振东，张秋实，徐立新.降纤酶联合长春西汀对急性脑梗死患者的临床治疗疗效观察[J].中国医药指南，2015，13（6）：175.
[7]	廖小英，周慧，李艳卿.依达拉奉联合奥拉西坦治疗大面积脑梗死的效果观察[J].中国当代医药，2015，22（31）：130-133.
[8]	Lyu T，Zhao Y，Zhang T，et al.Effect of statin pretreatment onmyocardial perfusion in patients undergoing primary percutaneous coronary intervention：a systematic review and Meta-analysis[J].Clin Cardiol，2013，36（9）：E17-E24.
[9]	卫明圣.脑心通与阿司匹林联合治疗腔隙性脑梗死的疗效观察[J].临床合理用药，2012，5（11B）：53-54.
[10]	魏芳，汤永红，刘卓然.急性脑梗死患者血清白细胞介素-18水平及临床意义[J].南华大学学报，2015，35（5）：719-722.
[11]	宋欣，蒋丽萍，李林萌，等.血浆APTT、FIB、D-二聚体和hs-CRP检测在脑梗死患者中的临床意义[J].中国现代医生，2014，52（3）：65-67.
[12]	刘一尔，林燕妮.依达拉奉治疗急性脑梗死疗效分析[J].中国当代医学，2011，17（27）：145-146.
[13]	罗鸿波，陈菱菱，李丽萍.依达拉奉联合丁苯酞治疗脑梗死疗效观察[J].当代医学，2014，20（12）：130-132.
[14]	朱以诚，崔丽英，高山，等.丁苯酞注射液治疗急性脑梗死的多中心、随机、双盲双模拟、对照Ⅲ期临床试验[J].中华神经科杂志，2014，47（2）：113-118.
[15]	肖桂荣，王赵伟，朱仁洋，等.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国神经免疫学和神经病学杂志，2016，17（1）：51-53.
[16]	沃静波.丁苯酞软胶囊联合复方丹参注射液治疗急性缺血性脑卒中临床疗效分析[J].海峡药学，2013，25（14）：133-135．